Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial

Jeremić, Branislav; Shibamoto, Yuta; Stanisavljević, B; Milojevic, Ljubisa; Miličić, Biljana; Nikolic, Nebojsa

doi:10.1016/s0167-8140(97)00048-0

Cited by 237 publications

(151 citation statements)

References 30 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…In a comparison of radiation therapy alone or with either cisplatin or carboplatin in these patients, two randomized trials reported the superiority of either combination arm to the radiation therapy alone arm, with no statistical difference between the two combination arms. 13,14 Mitomycin C also possesses most of the radiopotentiation mechanisms of interaction with radiation therapy (Table 2). Randomized trials comparing radiation therapy with or without mitomycin C showed improved local control but no differences in overall survival between the two groups.…”

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Al‐Sarraf

2002

Cancer Control

104

View full text Add to dashboard Cite

Background Advanced squamous cell cancers of the head and neck have traditionally been associated with high rates of morbidity and mortality. Advances in management have improved outcomes for most of these patients. Methods The author reviews the historical progress in management of these difficult tumors and adds his own wide experience to describe and evaluate newer approaches to management. Results Over the last 10 years, overall survival rates for patients with head and neck cancers have improved as has quality of life. New standards of care have been defined for patients with nasopharyngeal cancer and for those with advanced unresectable disease. Organ preservation is more commonly achieved. Conclusions Newer targeted therapies are likely to add to the progress that has already been achieved in the multimodality management of patients with head and neck cancers.

show abstract

Section: Concurrent Chemoradiotherapymentioning

confidence: 99%

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Al‐Sarraf

2002

Cancer Control

104

View full text Add to dashboard Cite

show abstract

“…In studies of patients with locally advanced head and neck cancer, significantly longer survival rates were seen in the patients receiving concurrent radiotherapy and carboplatin, and the only major toxicity was manageable myelosuppression [14,15]. However, the benefit for GBM patients treated with carboplatin and radiotherapy remains modest [16,17].…”

Section: Introductionmentioning

confidence: 99%

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

et al. 2009

View full text Add to dashboard Cite

Despite significant advances, the radiotherapy and chemotherapy protocols marginally improve the overall survival of patients with glioblastoma. Lipoplatin ™ , and Lipoxal ™ , the liposomal formulations of cisplatin and oxaliplatin respectively, were tested on the F98 glioma cells for their ability to improve the cell uptake and increase the synergic effect when combined with ionizing radiation. The cytotoxicity and synergic effect of platinum compounds were assessed by colony formation assay, while the cellular uptake was measured by Inductively Coupled Plasma Mass Spectrometer (ICP-MS). After 4 h exposure with platinum compounds, cells were irradiated (1.5 to 6.6 Gy) with a 60 Co source. The liposomal formulations were compared to their liposome-free analogs and to carboplatin. The concomitant treatment of F98 cells with carboplatin and radiation produced the highest radiosensitizing effect (30-fold increase). Among the platinum compounds tested, Lipoplatin ™ produced the most promising results. This liposomal formulation of cisplatin improved the cell uptake by 3-fold, and its radiosensitizing potential was enhanced by 14-fold. Although Lipoxal ™ can potentially reduce the adverse effect of oxaliplatin, a synergic effect with radiation was measured only when incubated at a concentration higher than its IC50. Conversely, concomitant treatment with cisplatin did not result in a synergic effect, as in fact a radioprotective effect was measured on the F98 cells. In conclusion, among the five platinum compounds tested, carboplatin and Lipoplatin ™ showed the best radiosensitizing effect. Lipoplatin ™ seems the most promising since it led to the best cellular incorporation and has already been reported to be less neurotoxic than other platinum compounds.

show abstract

“…Therefore, concomitant chemoradiation is more suitable as a curative treatment option in these patients. [2][3][4][5][6][7][8] Clinical trials comparing different treatment schedules (e.g., differences in the route of administration route [intraarterial vs. intravenous], chemotherapy dose, and radiation schedules) are ongoing to optimize the concomitant delivery of chemotherapy and radiation. However, chemoradiation is frequently associated with serious toxicity.…”

mentioning

confidence: 99%

Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma

Broek

Rasch

Pameijer

et al. 2004

Cancer

View full text Add to dashboard Cite

BACKGROUNDConcurrent chemoradiation is being used increasingly to treat patients with advanced‐stage head and neck carcinoma. In the current study, a clinical nomogram was developed to predict local control and overall survival rates for individual patients who will undergo chemoradiation.METHODSNinety‐two consecutive patients with UICC TNM Stage III/IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and supraglottic larynx were treated with selective‐targeted chemoradiation (acronym: RADPLAT). All living patients had a minimum follow‐up of 2 years. In addition to general factors, the following parameters were analyzed in a multivariable analysis: primary tumor volume, lymph node tumor volume, total tumor volume, lowest involved neck level, comorbidity, pretreatment hemoglobin level, pretreatment weight loss, and unilateral/bilateral intraarterial infusion. Relevant factors for local control and survival were analyzed using the Cox proportional hazards model.RESULTSAt 5 years, the local control and overall survival rates for the whole group were 60% and 38%, respectively. Primary tumor volume (hazard ratio [HR], 1.03; P = 0.01) and unilateral infusion (HR, 5.05; P = 0.004) were found to influence local control significantly. Using tumor volume as a continuous variable, an adjusted risk ratio of 1.026 was found, indicating that each 1‐cm3 increase in volume was associated with a 2.6% decrease in probability of local control. Primary tumor volume (HR, 1.01; P = 0.003), comorbidity (American Society of Anesthesiologists [ASA] physical status 1 vs. > 1; HR, 2.47; P = 0.01), lowest involved neck level (HR, 3.45; P = 0.007), and pretreatment weight loss > 10% (HR, 2.04; P = 0.02) were found to be significant predictors of worse overall survival. Variables from the multivariable analysis were used to develop a nomogram capable of predicting local control and overall survival.CONCLUSIONSTumor volume was found to play a significant role in predicting local control and overall survival in patients with advanced‐stage head and neck carcinoma who were treated with targeted chemoradiation. The nomograms may be useful for pretreatment selection of patients with advanced‐stage head and neck carcinoma. Cancer 2004. © 2004 American Cancer Society.

show abstract

Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial

Cited by 237 publications

References 30 publications

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation

Pretreatment probability model for predicting outcome after intraarterial chemoradiation for advanced head and neck carcinoma

Contact Info

Product

Resources

About